Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYX-13 effects on learning and memory
NCT01844726Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- May 2013
- Primary completion
- Jan 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in schizophrenia and schizoaffective disorder comparing GLYX-13 with Placebo (2 arms). Primary endpoint: Percentage of Change in fMRI BOLD Signal During a Category Learning Task at 1 hour. Started May 2013; status: terminated.
02
Drugs
rapastinel
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT01844726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01844726.